Stock Price & Analysis

The S1 support level for XLO Stock is $0.71 ,The R1 resistant level for XLO Stock is $1.52.

As of the end of day on 2025-02-21, the price of XLO Stock was $0.895.

The target price for XLO Stock according to analyst rating is 4.50, with the highest price target at 5.00 and the lowest at 4.00. Analysts have a Moderate Buy rating on XLO Stock overall.

The market cap of XLO is $46.6M.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions platform to rapidly engineer molecules, including cytokines and other biologics. Its tumor-activated, clinical-stage product candidates are XTX202, an interleukin 2 (IL-2), therapy, XTX301, an interleukin 12 (IL-12), therapy and XTX101. Its XTX101 is designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment and improve upon the therapeutic index of existing anti-CTLA-4 therapies. Its XTX101 in an ongoing Phase I clinical trial in patients with advanced solid tumors. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and NK cells without concomitant stimulation of regulatory T cells.

XLO has a total of 73 employees.